Literature DB >> 28282486

Determination of a No-Observable Effect Level for Endotoxin Following a Single Intravitreal Administration to Dutch Belted Rabbits.

Vladimir Bantseev1, Paul E Miller2, Ellison Bentley2, Chris Schuetz1, Tim M Streit3, Brian J Christian3, Cindy Farman4, Helen Booler1, Evan A Thackaberry1.   

Abstract

Purpose: The purpose of this study was to characterize the inflammatory response and determine a no-observable effect level (NOEL) in rabbit eyes after endotoxin intravitreal (ITV) injection.
Methods: Fifty-three naïve male Dutch Belted rabbits were treated with a single 50-μL ITV injection ranging from 0.01 to 0.75 endotoxin units/eye (EU/eye) and monitored for up to 42 days post treatment. Ophthalmic examination included slit-lamp biomicroscopy and indirect ophthalmoscopy. Laser flare photometry was performed in a subset of animals. On days 2, 8, 16, and 43, a subset of animals was necropsied and eyes processed for histopathological evaluation.
Results: Intravitreal injection of endotoxin at ≥0.05 EU/eye resulted in a dose-related anterior segment inflammation response. No aqueous flare or cell response was noted in the 0.01 EU/eye dose group. A more delayed posterior segment response characterized by vitreal cell response was observed beginning on day 5, peaking on day 9, and decreasing starting on day 16 that persisted at trace to a level of 1+ on day 43. Microscopy findings of infiltrates of minimal mixed inflammatory cells in the vitreous and subconjunctiva and proteinaceous fluid in the anterior chamber and/or vitreous were observed in eyes given ≥0.1 EU/eye. Conclusions: We defined the NOEL for ITV endotoxin to be 0.01 EU/eye, suggesting that the vitreal cavity is more sensitive to the effects of endotoxin than the anterior segment and aqueous chamber. These data highlight the importance of assessing endotoxin level in intravitreal formulations, as levels as low as 0.05 EU/eye may confound the safety evaluations of intravitreal therapeutics in rabbits.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28282486     DOI: 10.1167/iovs.16-21356

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Determination of a No Observable Effect Level for Endotoxin Following a Single Intravitreal Administration to Cynomolgus Monkeys.

Authors:  Vladimir Bantseev; Paul E Miller; T Michael Nork; Carol A Rasmussen; Aija McKenzie; Brian J Christian; Helen Booler; Evan A Thackaberry
Journal:  J Ocul Pharmacol Ther       Date:  2019-04-09       Impact factor: 2.671

Review 2.  Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space.

Authors:  Eric Wakshull; Valerie Quarmby; Hanns-Christian Mahler; Hongwen Rivers; Dhananjay Jere; Meg Ramos; Piotr Szczesny; Karoline Bechtold-Peters; Sharmila Masli; Swati Gupta
Journal:  AAPS J       Date:  2017-08-09       Impact factor: 4.009

3.  Extended Intravitreal Rabbit Eye Residence of Nanoparticles Conjugated With Cationic Arginine Peptides for Intraocular Drug Delivery: In Vivo Imaging.

Authors:  Ignacio Melgar-Asensio; Irawati Kandela; Fraser Aird; Soesiawati R Darjatmoko; Cristobal de Los Rios; Christine M Sorenson; Daniel M Albert; Nader Sheibani; Jack Henkin
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-08-01       Impact factor: 4.799

4.  Evaluation of the Dose-Dependent Inflammatory Response and No-Observable Adverse Effect Level of Intravitreal Endotoxin in the African Green Monkey.

Authors:  Tatiana M Corey; Vernard V Woodley; Merissa O'Connor; Emma Connolly; Sarah Doyle; Stephanie Shrader; Cyrene Phipps; Kimicia Isaac; Matthew Lawrence
Journal:  Transl Vis Sci Technol       Date:  2022-08-01       Impact factor: 3.048

5.  Systemic anti-inflammatory therapy aided by double-headed nanoparticles in a canine model of acute intraocular inflammation.

Authors:  R Ganugula; M Arora; M A Lepiz; Y Niu; B K Mallick; S C Pflugfelder; E M Scott; M N V Ravi Kumar
Journal:  Sci Adv       Date:  2020-08-26       Impact factor: 14.136

6.  Pharmacokinetics of Pullulan-Dexamethasone Conjugates in Retinal Drug Delivery.

Authors:  Eva Kicková; Amir Sadeghi; Jooseppi Puranen; Shirin Tavakoli; Merve Sen; Veli-Pekka Ranta; Blanca Arango-Gonzalez; Sylvia Bolz; Marius Ueffing; Stefano Salmaso; Paolo Caliceti; Elisa Toropainen; Marika Ruponen; Arto Urtti
Journal:  Pharmaceutics       Date:  2021-12-21       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.